Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Medpace Holdings Inc. (MEDP)

NASDAQ: MEDP · Services-Commercial Physical & Biological Research · Cincinnati, OH

Our rating: Neutral

Call changed from Positive to Neutral at $669.20, moderate conviction, October 23, 2026.

Breaks if: The Neutral call turns Cautious if Medpace reports revenue growth below 12% in two consecutive quarterly filings — a signal the biotech funding cycle has tightened enough to undercut the growth premium the 43.8× multiple depends on. It turns Positive if the stock pulls back 20% or more from current levels without a parallel deterioration in backlog or operating margin over the same period.

Key figures

Market value$17.1B
Revenue, last 12 months$2.8B
Net income, last 12 months$518M
Free cash flow, last 12 months$668M
Price to earnings33.0×
Free cash flow yield3.9%
Dividend yield0.0%
Operating margin21.4%
Return on equity117.9%
Beta to the S&P 5000.93
Volatility, annualized54.4%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$716M8.5%$4.84$196M
June 30, 2026$707M17.2%$4.25$138M
March 31, 2026$707M26.5%$4.28$145M
December 31, 2025$708M32.0%$4.64$188M
September 30, 2025$660M23.7%$3.86$235M
June 30, 2025$603M14.2%$3.10$142M
March 31, 2025$559M9.3%$3.67$116M
December 31, 2024$537M7.7%$3.67$183M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

11 ledger entries and 34 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.